There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inhibikase Therapeutics (IKT – Research Report) and Mustang Bio (MBIO – Research Report) with bullish sentiments.
Inhibikase Therapeutics (IKT)
In a report issued on November 17, Soumit Roy from JonesTrading maintained a Buy rating on Inhibikase Therapeutics, with a price target of $12.00. The company’s shares closed last Friday at $1.90, close to its 52-week low of $1.72.
According to TipRanks.com, Roy is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inhibikase Therapeutics with a $12.00 average price target.
Mustang Bio (MBIO)
B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Mustang Bio on November 17 and set a price target of $13.00. The company’s shares closed last Friday at $2.27, close to its 52-week low of $2.10.
According to TipRanks.com, Mamtani is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mustang Bio with a $10.00 average price target, implying a 340.5% upside from current levels. In a report issued on November 12, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IKT: